ESSA Pharma Inc.
EPIX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 50% |
| R&D Expenses | -$1 | $3 | $5 | $4 |
| G&A Expenses | $6 | $4 | $4 | $4 |
| SG&A Expenses | $6 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$0 |
| Operating Expenses | $5 | $7 | $10 | $8 |
| Operating Income | -$5 | -$7 | -$10 | -$8 |
| % Margin | – | – | – | -5,668% |
| Other Income/Exp. Net | $1 | $1 | $1 | $1 |
| Pre-Tax Income | -$4 | -$6 | -$9 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$6 | -$9 | -$6 |
| % Margin | – | – | – | -4,681.4% |
| EPS | -0.09 | -0.14 | -0.19 | -0.14 |
| % Growth | 35.6% | 26.3% | -35.7% | – |
| EPS Diluted | -0.09 | -0.14 | -0.19 | -0.14 |
| Weighted Avg Shares Out | 44 | 44 | 44 | 44 |
| Weighted Avg Shares Out Dil | 44 | 44 | 44 | 44 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $0 |
| EBITDA | -$5 | -$6 | -$9 | -$6 |
| % Margin | – | – | – | -4,664.6% |